

Supplement Table 4. Clinical outcomes among patients with different types of ARBs

ARB drugs	Incidence rate		Unadjusted		Adjusted	
	Number of cases	(per 1,000 person-years)	HR (95% CI)	p-value	HR (95% CI)	p-value
All-cause death						
Fimasartan	6	22.4	0.50 (0.22–1.12)	0.09	0.70 (0.30–1.63)	0.41
Candesartan	113	54.3	1.36 (0.99–1.87)	0.06	1.32 (1.04–1.66)*	0.02
Valsartan	76	38.0	0.83 (0.61–1.12)	0.22	0.82 (0.62–1.08)	0.16
Losartan	64	33.6	0.72 (0.51–1.02)	0.07	0.83 (0.64–1.08)	0.16
Telmisartan	38	64.3	1.53 (1.06–2.21)*	0.02	1.24 (0.85–1.80)	0.27
Olmesartan	19	44.3	1.01 (0.65–1.56)	0.97	1.04 (0.60–1.78)	0.90
Irbesartan	18	50.1	1.16 (0.67–1.99)	0.60	0.94 (0.53–1.64)	0.82
Recurrent myocardial infarction						
Fimasartan	5	19.4	1.30 (0.50–3.35)	0.59	1.28 (0.49–3.34)	0.61
Candesartan	26	12.8	0.82 (0.52–1.30)	0.40	0.75 (0.48–1.17)	0.21
Valsartan	30	15.4	1.14 (0.80–1.62)	0.47	1.20 (0.85–1.71)	0.30
Losartan	23	12.3	0.91 (0.54–1.56)	0.74	0.94 (0.55–1.62)	0.83
Telmisartan	9	15.5	1.08 (0.62–1.88)	0.80	1.12 (0.64–1.95)	0.69
Olmesartan	6	14.8	1.01 (0.42–2.43)	0.99	1.01 (0.41–2.48)	0.98

Irbesartan	6	17.0	1.29 (0.57–2.93)	0.54	1.22 (0.53–2.77)	0.64
Hospitalization for heart failure						
Fimasartan	5	18.9	0.62 (0.21–1.79)	0.37	0.70 (0.27–1.84)	0.47
Candesartan	63	31.4	1.08 (0.67–1.73)	0.75	0.93 (0.63–1.38)	0.72
Valsartan	59	30.9	1.11 (0.71–1.75)	0.65	1.15 (0.76–1.75)	0.51
Losartan	42	22.9	0.81 (0.56–1.18)	0.26	0.98 (0.67–1.43)	0.92
Telmisartan	19	33.9	1.17 (0.72–1.89)	0.54	1.09 (0.70–1.70)	0.70
Olmesartan	12	29.1	0.99 (0.55–1.78)	0.96	0.98 (0.55–1.76)	0.95
Irbesartan	10	29.1	1.06 (0.56–1.99)	0.87	0.92 (0.49–1.73)	0.80
Stroke						
Fimasartan	2	7.5	0.47 (0.13–1.61)	0.23	0.59 (0.18–1.96)	0.39
Candesartan	25	12.2	0.72 (0.43–1.20)	0.20	0.72 (0.43–1.20)	0.21
Valsartan	34	17.5	1.23 (0.83–1.84)	0.30	1.23 (0.80–1.90)	0.34
Losartan	28	15.2	1.06 (0.68–1.65)	0.81	1.08 (0.67–1.74)	0.75
Telmisartan	15	26.7	1.81 (0.87–3.75)	0.11	1.83 (0.91–3.69)	0.09
Olmesartan	5	11.9	0.76 (0.31–1.89)	0.56	0.74 (0.31–1.79)	0.51
Irbesartan	4	11.2	0.75 (0.29–1.92)	0.55	0.56 (0.20–1.54)	0.26

The reference group for hazard ratios was sum of the other ARBs, and HRs were adjusted for age, sex, previous revascularization, previous ARB or angiotensin-converting enzyme inhibitor therapy, diabetes mellitus, hypertension, hyperlipidemia, atrial fibrillation or flutter, chronic obstructive pulmonary disease, peripheral artery disease, malignancy, admission at tertiary hospital, and discharge medications.

*p< 0.05, **p< 0.01, ***p< 0.001

Abbreviations: ARB, angiotensin receptor blocker; CI, confidence interval; HR, hazard ratio.